Orchid Pharma locked at upper circuit on USFDA nod

The company has received ANDA approval from USFDA for Risedronate Sodium Tablets USP, 30 mg and 35 mg.

Shares of Orchid Pharma locked at the upper circuit on May 15 on the back of USFDA nod for Risedronate Sodium Tablets.


At 09:24 hrs Orchid Pharma was quoting at Rs 4, up to Rs 0.17, or 4.44 percent.

There were pending buy orders of 33,257 shares, with no sellers available.

The company has received ANDA approval from the United States Food and Drug Administration (USFDA) for Risedronate Sodium Tablets USP, 30 mg and 35 mg.

Risedronate sodium tablets are a bisphosphonate indicated for the treatment and prevention of Osteoporosis.

Get Stock Market Tips and MCX Tips to start from 2 Days Free Trial Click Here- Stock Market Tips, MCX Tips “We Provide Secure, and Smooth Deals You Can Trust”

You May Also Like

0 comments

Note: only a member of this blog may post a comment.